Note: Descriptions are shown in the official language in which they were submitted.
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
2-ALKYLIDENE-19-NOR-VITAMIN D COMPOUNDS AND THEIR THERAPEUTIC USES
BACKGROUND OF THE INVENTION
This patent invention relates to vitamin D compounds, and more particularly to
vitainin D derivatives substituted at the carbon 2 position.
The natural hormone, la,25-dihydroxyvitamin D3 and its analog in ergosterol
series,
i.e. 1a,25-dihydroxyvitamin D2 are lcnown to be highly potent regulators of
calcium
homeostasis in animals and humans, and more recently their activity in
cellular differentiation
has been established, Ostrem et al., Proc. Natl. Acad. Sci. USA, 84, 2610
(1987). Many
structural analogs of these metabolites have been prepared and tested,
including 1 a-
hydroxyvitamin D3, 1 a-hydroxyvitamin D2, various side chain homologated
vitamins and
fluorinated analogs. Some of these compounds exhibit an interesting separation
of activities in
cell differentiation and calcium regulation. This difference in activity may
be useful in the
treatment of a variety of diseases such as renal osteodystrophy, vitamin D-
resistant rickets,
osteoporosis, psoriasis, and certain malignancies.
Recently, a new class of vitamin D analogs has been discovered, i.e. the so
called 19-
nor-vitamin D compounds, which are characterized by the replacement of the A-
ring exocyclic
methylene group (carbon 19), typical of the vitamin D system, by two hydrogen
atoms.
-1-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Biological testing of such 19-nor-analogs (e.g., 1 a,25-dihydroxy- 1 9-nor-
vitamin D3) revealed
a selective activity profile with high potency in inducing cellular
differentiation, and very low
calcium mobilizing activity. Thus, these compounds are potentially useful as
therapeutic
agents for the treatment of malignancies, or the treatment of various skin
disorders. Two
different methods of synthesis of such 19-nor-vitamin D analogs have been
described
(Perlman et al., Tetrahedron Lett. 31, 1823 (1990); Perlman et al.,
Tetrahedron Lett. 32, 7663
(1991), and DeLuca et al., U.S. Pat. No. 5,086,191).
In U.S. Pat. No. 4,666,634, 2(3-hydroxy and alkoxy (e.g., ED-71) analogs of
1a,25-
dihydroxyvitamin D3 have been described and examined by Chugai group as
potential drugs
for osteoporosis and as antitumor agents. See also Okano et al., Biochem.
Biophys. Res.
Commun. 163, 1444 (1989). Other 2-substituted (with hydroxyalkyl, e.g., ED-
120, and
fluoroalkyl groups) A-ring analogs of 1 a,25-dihydroxyvitamin D3 have also
been prepared
and tested (Miyamoto et al., Chem. Pharm. Bull. 41, 1111 (1993); Nishii et
al., Osteoporosis
Int. Suppl. l, 190 (1993); Posner et al., J. Org. Chem. 59, 7855 (1994), and
J. Org. Chem. 60,
4617 (1995)).
Recently, 2-substituted analogs of 1 a,25 -dihydroxy- 1 9-norvitamin D3 have
also been
synthesized, i.e. compounds substituted at 2-position with hydroxy or alkoxy
groups (DeLuca
et al., U.S. Pat. No. 5,536,713), which exhibit interesting and selective
activity profiles. All
these studies indicate that binding sites in vitamin D receptors can
accommodate different
substituents at C-2 in the synthesized vitamin D analogs.
In a continuing effort to explore the 19-nor class of pharmacologically
important
vitamin D compounds, their analogs which are characterized by the presence of
an alkylidene
(particularly methylene) substituent at the carbon 2 (C-2), i.e. 2-alkylidene-
19-nor-vitaYnin D
compounds, have now been synthesized and tested. Of particular interest are
the analogs
which are characterized by the transposition of the ring A exocyclic methylene
group, present
in the normal vitamin D skeleton, from carbon 10 (C-10) to carbon 2 (C-2),
i.e. 2-methylene-
19-nor-vitamin D compounds. Such vitamin D analogs seemed interesting targets
because the
relatively small alkylidene (particularly methylene) group at C-2 should not
interfere with
vitamin D receptor. Moreover, molecular mechanics studies performed on the
model la-
hydroxy-2-methylene- 1 9-nor-vitamins indicate that such molecular
modification does not
change substantially the conformation of the cyclohexanediol ring A. However,
introduction
of the 2-methylene group into 19-nor-vitamin D carbon skeleton changes the
character of its
-2-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
l a- and 3 f3- A-ring hydroxyls. They are both now in the allylic positions,
similarly, as 1 a-
hydroxyl group (crucial for biological activity) in the molecule of the
natural hormone, 1 a,25-
(OH)2D3.
SUMMARY OF THE INVENTION
A class of 1 a-hydroxylated vitamin D compounds not known heretofore are the
19-
nor-vitamin D analogs having an alkylidene (particularly methylene) group at
the 2-position,
i.e. 2-alkylidene- 1 9-nor-vitamin D compounds, particularly 2-methylene-l9-
nor-vitamin D
compounds. These latter compounds are those in which the A-ring exocyclic
methylene group
typical of all vitamin D system has been transposed to the carbon 2, i.e. 19-
nor-vitamin D
analogs having a methylene group at the 2-position.
Structurally these novel analogs are characterized by the general formula I
shown below:
H
( I
.
0
Y2O~`1OYl
R6 R8
where Y1 and Y2, which may be the same or different, are each selected from
the group
consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be
the same or
different, are each selected from the group consisting of hydrogen, alkyl,
hydroxyalkyl and
fluoroalkyl, or, when taken together represent the group -(CH2)X where X is an
integer from
2 to 5, and where the group R represents any of the typical side chains known
for vitamin D
type compounds.
-3-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
More specifically R can represent a saturated or unsaturated hydrocarbon
radical of 1
to 35 carbons, that may be straight-chain, branched or cyclic and that may
contain one or more
additional substituents, such as hydroxy- or protected-hydroxy groups, fluoro,
carbonyl, ester,
epoxy, amino or other heteroatomic groups. Preferred side chains of this type
are represented
by the structure below
Yz
LZ')
where the stereochemical center (corresponding to C-20 in steroid numbering)
may have the R
or S configuration, (i.e. either the natural configuration about carbon 20 or
the 20-epi
configuration), and where Z is selected from Y, -OY, -CH2OY, -C=CY, CH=CHY,
and
-CH2CH2CH=CR3R4, where the double bond may have the cis or trans geometry, and
where Y
is selected from hydrogen, methyl, -COR5 and a radical of the structure:
R~ R2 R3
/
(CH2)m C - (CH2)n -C~ R5
R4
where m and n, independently, represent the integers from 0 to 5, where Rl is
selected from
hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and
C1-5-alkyl,
which may be straight chain or branched and, optionally, bear a hydroxy or
protected-hydroxy
substituent, and where each of R2, R3, and R4, independently, is selected from
deuterium,
deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be
straight-chain
or branched, and optionally, bear a hydroxy or protected-hydroxy substituent,
and where Rl
and R2, taken together, represent an oxo group, or an alkylidene group,
=CR2R3, or the group
-(CH2)p , where p is an integer from 2 to 5, and where R3 and R4, taken
together, represent
an oxo group, or the group -(CH2)q , where q is an integer from 2 to 5, and
where R5
represents hydrogen, hydroxy, protected hydroxy, C1-5 alkyl or -OR7 where R7
represents Cl_5
alkyl, and wherein any of the CH-groups at positions 20, 22, or 23 in the side
chain may be
-4-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
replaced by a nitrogen atom, or where any of the groups -CH(CH3)-, -CH(R3)-,
or -CH(R2)-
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or
sulfur atom.
The wavy line to the methyl substituent at C-20 indicates that carbon 20 may
have
either the R or S configuration.
Specific important examples of side chains with natural 20R-configuration are
the
structures represented by formulas (a), b), (c), (d) and (e) below. i.e. the
side chain as it occurs
in 25-hydroxyvitamin D3 (a); vitamin D3 (b); 25-hydroxyvitamin D2 (c); vitamin
D2 (d); and
the C-24 epimer of 25-hydroxyvitamin D2 (e):
(a)
OH
(b)
dv~n^
X.,
(c)
OH
(d)
(e)
OH
VIV V\^
-5-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Specific important examples of side chains with the unnatural 20(S) (also
referred to as the 20-epi) configuration are the structures represented by
formulas (f), (g),
(h), and (i) below:
OH
(g)
OH
OCH3
(h)
(i)
The above novel compounds exhibit a desired, and highly advantageous, pattern
of
biological activity. These compounds are characterized by relatively high
intestinal calcium
transport activity, as compared to that of la,25-dihydroxyvitamin D3, while
also exhibiting
relatively high activity, as compared to 1a,25-dihydroxyvitamin D3, in their
ability to
mobilize calcium from bone. Hence, these compounds are highly specific in
their calcemic
activity. Their preferential activity on mobilizing calcium from bone and
either high or
normal intestinal calcium transport activity allows the in vivo administration
of these
-6-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
compounds for the treatment of metabolic bone diseases where bone loss is a
major concern.
Because of their preferential calcemic activity on bone, these compounds would
be preferred
therapeutic agents for the treatment of diseases where bone formation is
desired, such as
osteoporosis, especially low bone turnover osteoporsis, steroid induced
osteoporosis, senile
osteoporosis or postmenopausal osteoporosis, as well as osteomalacia and renal
osteodystrophy. The treatment may be transdermal, oral or parenteral. The
compounds may
be present in a composition in an amount from about 0.1 g/gm to about 50 g/gm
of the
composition, and may be administered in dosages of from about 0.1 g/day to
about 50 g/day.
The compounds of the invention are also especially suited for treatment and
prophylaxis of human disorders which are characterized by an imbalance in the
immune
system, e.g. in autoimmune diseases, including multiple sclerosis, diabetes
mellitus, host
versus graft reaction, and rejection of transplants; and additionally for the
treatment of
inflammatory diseases, such as rheumatoid arthritis and asthma, as well as the
improvement of
bone fracture healing and improved bone grafts. Acne, alopecia, skin
conditions such as dry
skin (lack of dermal hydration), undue skin slackness (insufficient skin
firmness), insufficient
sebum secretion and wrinkles, and hypertension are other conditions which may
be treated
with the compounds of the invention.
The above compounds are also characterized by high cell differentiation
activity.
Thus, these compounds also provide therapeutic agents for the treatment of
psoriasis, or as an
anti-cancer agent, especially against leukemia, colon cancer, breast cancer
and prostate cancer.
The compounds may be present in a composition to treat psoriasis in an amount
from about
0.01 g/gm to about 100 g/gm of the composition, and may be administered
topically,
transdermally, orally or parenterally in dosages of from about 0.01 g/day to
about 100 g/day.
This invention also provides novel intermediate compounds formed during the
synthesis of the end products. Structurally, these novel intermediates are
characterized by the
general formulae V, VI, VII, VIII, IX and X below where Y1, Y2, R6 and Rg are
as
previously defined herein.
AIkyIOOCs OH
.,..
Y20'~ ~ oY, V
R6 R$
-7-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
HOH2C" OH
'~.
VI
Y2OY1
R6 R8
0
VII
Y2OY1
R6 R8
COOAIkyI
VIII
Y2O~ ll oY,
Rs/ `R8
CH2OH
IX
Y20~ A OY,
R6 R$
CH2POPh2
x
Y20~~` OY,
R6 R$
-8-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
This invention also provides a novel synthesis for the production of the end
products
of structure I.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph illustrating the relative activity of 2-methylene-19-nor-
20(S)-
1a,25-dihydroxyvitamin D3, 2-methylene-19-nor-la,25-dihydroxyvitamin D3 and
1a,25-
dihydroxyvitamin D3 to compete for binding of [3H]-1,25-(OH)2-D3 to the
vitamin D pig
intestinal nuclear receptor; and
Figure 2 is a graph illustrating the percent HL-60 cell differentiation as a
function of
the concentration of 2-methylene-19-nor-20(S)-1a,25-dihydroxyvitamin D3, 2-
methylene-19-
nor-1a,25-dihydroxyvitamin D3 and 1a,25-dihydroxyvitamin D3.
DETAILED DESCRIPTION OF THE INVENTION
As used in the description and in the claims, the term "hydroxy-protecting
group'
signifies any group commonly used for the temporary protection of hydroxy
functions, such as
for example, alkoxycarbonyl, acyl, alkylsilyl or alkylarylsilyl groups
(hereinafter referred to
simply as "silyl" groups), and alkoxyalkyl groups. Alkoxycarbonyl protecting
groups are
alkyl-O-CO- groupings such as methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl,
isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
benzyloxycarbonyl or allyloxycarbonyl. The term "acyl" signifies an alkanoyl
group of 1 to 6
carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6
carbons, such as an
oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such as
benzoyl, or a halo,
nitro or alkyl substituted benzoyl group. The word "alkyl" as used in the
description or the
claims, denotes a straight-chain or branched alkyl radical of 1 to 10 carbons,
in all its isomeric
forms. Alkoxyalkyl protecting, groups are groupings such as methoxymethyl,
ethoxymethyl,
methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl. Preferred
silyl-protecting
groups are trimethylsilyl, triethylsilyl, t-butyldimethylsilyl,
dibutylmethylsilyl,
diphenylmethylsilyl, phenyldimethylsilyl, diphenyl-t-butylsilyl and analogous
alkylated silyl
radicals. The term "aryl" specifies a phenyl-, or an alkyl-, nitro- or halo-
substituted phenyl
group.
A "protected hydroxy" group is a hydroxy group derivatised or protected by any
of
the above groups commonly used for the temporary or permanent protection of
hydroxy
functions, e.g. the silyl, alkoxyalkyl, acyl or alkoxycarbonyl groups, as
previously defined.
-9-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
The terms "hydroxyalkyl", "deuteroalkyl" and "fluoroalkyl" refer to an alkyl
radical
substituted by one or more hydroxy, deuterium or fluoro groups respectively.
It should be noted in this description that the term "24-homo" refers to the
addition
of one methylene group and the term "24-dihomo" refers to the addition of two
methylene
groups at the carbon 24 position in the side chain. Likewise, the term
"trihomo" refers to the
addition of three methylene groups. Also, the term "26,27-dimethyl" refers to
the addition of
a methyl group at the carbon 26 and 27 positions so that for example R3 and R4
are ethyl
groups. Likewise, the term "26,27-diethyl" refers to the addition of an ethyl
group at the 26
and 27 positions so that R3 and R4 are propyl groups.
In the following lists of compounds, the particular alkylidene substituent
attached at
the carbon 2 position should be added to the nomenclature. For example, if a
methylene
group is the alkylidene substituent, the term "2-methylene" should precede
each of the named
compounds. If an ethylene group is the alkylidene substituent, the term "2-
ethylene" should
precede each of the named compounds, and so on. In addition, if the methyl
group attached at
the carbon 20 position is in its epi or unnatural configuration, the term
"20(S)" or "20-epi"
should be included in each of the following named compounds. The named
compounds could
also be of the vitamin D2 type if desired.
Specific and preferred examples of the 2-alkylidene-compounds of structure I
when
the side chain is unsaturated are:
19-nor-24-homo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dimethyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-diethyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dipropoyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D3;
19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D3; and
19-nor-26,27-dimethylene-1-hydroxy-24-dehydrovitamin D3.
-10-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
A particularly preferred side chain unsaturated compound is:
19-nor-26,27-dimethylene-20(S)-2-methylene-1 a-hydroxy-24-dehydrovitamin D3.
Specific and preferred examples of the 2-alkylidene-compounds of structure I
when
the side chain is saturated are:
19-nor-24-homo- 1,25 -dihydroxyvitamin D3;
19-nor-24-dihomo-1,25-dihydroxyvitamin D3;
19-nor-24-trihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dimethyl-24-homo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dimethyl-24-dihoino-1,25-dihydroxyvitamin D3;
19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-diethyl-24-homo- 1,25 -dihydroxyvitamin D3;
19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dipropyl-24-homo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxyvitamin D3;
19-nor-26,27-dimethyl-1,25-dihydroxyvitamin D3;
19-nor-26,27-dimethylene-1,25-hydroxyvitamin D3; and
19-nor-26,27-dimethylene-l-hydroxy-25-methoxyvitamin D3.
As noted previously, the above saturated side chain compounds should have the
appropriate 2-
allcylidene substituent and/or carbon 20 configuration added to the
nomenclature., For
example, particularly preferred saturated side chain compounds are:
19-nor-26,27-dimethyl-20(S)-2-methylene-1a,25-dihydroxyvitamin D3; which can
also be written as 19-nor-26,27-dihomo-20(S)-2-methylene-1a,25-
dihydroxyvitamin D3;
19-nor-26,27-dimethylene-20(S)-2-methylene-1a,25-dihydroxyvitamin D3; and
19-nor-26,27-dimethylene-20(S)-2-methylene-1 a-hydroxy-25-methoxyvitamin D3.
The preparation of 1a-hydroxy-2-alkylidene-19-nor-vitamin D compounds,
particularly 1a-hydroxy-2-methylene-19-nor-vitamin D compounds, having the
basic
structure I can be accomplished by a common general method, i.e. the
condensation of a
bicyclic Windaus-Grundmann type ketone II with the allylic phosphine oxide III
to the
corresponding 2-methylene-19-nor-vitamin D analogs IV followed by deprotection
at C-1 and
C-3 in the latter compounds:
-11-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
R
OPPh2
R
IV
III :OY,
H O Y20 OY, N`~~.
Y20 In the structures II, III, and IV groups Yl and Y2 and R represent groups
defined above; Y1
and Y2 are preferably hydroxy-protecting groups, it being also understood that
any
functionalities in R that might be sensitive, or that interfere with the
condensation reaction, be
suitable protected as is well-known in the art. The process shown above
represents an
application of the convergent synthesis concept, which has been applied
effectively for the
preparation of vitamin D compounds [e.g. Lythgoe et al., J. Chem. Soc. Perkin
Trans. I, 590
(1978); Lythgoe, Chem. Soc. Rev. 9, 449 (1983); Toh et al., J. Org. Chem. 48,
1414 (1983);
Baggiolini et al., J. Org. Chem. 51, 3098 (1986); Sardina et al., J. Org.
Chem. 51, 1264
(1986); J. Org. Chem. 51, 1269 (1986); DeLuca et al., U.S. Pat. No. 5,086,191;
DeLuca et al.,
U.S. Pat. No. 5,536,713].
Hydrindanones of the general structure II are known, or can be prepared by
known
methods. Specific important examples of such known bicyclic ketones are the
structures with
the side chains (a), (b), (c) and (d) described above, i.e. 25-hydroxy
Grundmann's ketone (f)
[Baggiolini et al., J. Org. Chem, 51, 3098 (1986)]; Grundmann's ketone (g)
[Inhoffen et al.,
Chem. Ber. 90, 664 (1957)]; 25-hydroxy Windaus ketone (h) [Baggiolini et al.,
J. Org. Chem.,
51, 3098 (1986)] and Windaus ketone (i) [Windaus et al., Ann., 524, 297
(1936)]:
M
OH
O H
-12-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
,'~~'~'=.
(9)
H
O H (h)
O H
~~~~'''== ` (~)
H
For the preparation of the required phosphine oxides of general structure III,
a new
synthetic route has been developed starting from methyl quinicate derivative
1, easily obtained
from commercial (1R,3R,4S,5R)-(-)-quinic acid as described by Perlman et al.,
Tetrahedron
Lett. 32, 7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191. The overall
process of
transformation of the starting methyl ester 1 into the desired A-ring
synthons, is summarized
by the SCHEME I. Thus, the secondary 4-hydroxyl group of 1 was oxidized with
Ru04 (a
catalytic method with RuC13 and NaIO4 as co-oxidant). Use of such a strong
oxidant was
necessary for an effective oxidation process of this very hindered hydroxyl.
However, other
more commonly used oxidants can also be applied (e.g. pyridinium dichromate),
although the
reactions usually require much longer time for completion. Second step of the
synthesis
-13-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
comprises the Wittig reaction of the sterically hindered 4-keto compound 2
with ylide
prepared from methyltriphenylphosphonium bromide and n-butyllithium. Other
bases can be
also used for the generation of the reactive methylenephosphorane, like t-
BuOK, NaNH2,
NaH, K/HMPT, NaN(TMS)2, etc. For the preparation of the 4-methylene compound 3
some
described modifications of the Wittig process can be used, e.g. reaction of 2
with activated
methylenetriphenyl-phosphorane [Corey et al., Tetrahedron Lett. 26, 555
(1985)].
Alternatively, other methods widely used for methylenation of unreactive
ketones can be
applied, e.g. Wittig-Horner reaction with the PO-ylid obtained from
methyldiphenylphosphine
oxide upon deprotonation with n-butyllithium [Schosse et al., Chimia 30, 197
(1976)], or
reaction of ketone with sodium methylsulfinate [Corey et al., J. Org. Chem.
28, 1128 (1963)]
and potassium methylsulfinate [Greene et al., Tetrahedron Lett. 3755 (1976)].
Reduction of
the ester 3 with lithium aluminum hydride or other suitable reducing agent
(e.g. DIBALH)
provided the dio14 which was subsequently oxidized by sodium periodate to the
cyclohexanone derivative 5. The next step of the process comprises the
Peterson reaction of
the ketone 5 with methyl(trimethylsilyl)acetate. The resulting allylic ester 6
was treated with
diisobutylaluminum hydride and the formed allylic alcohol 7 was in turn
transformed to the
desired A-ring phosphine oxide 8. Conversion of 7 to 8 involved 3 steps,
namely, in situ
tosylation with n-butyllithium and p-toluenesulfonyl chloride, followed by
reaction with
diphenylphosphine lithium salt and oxidation with hydrogen peroxide.
Several2-methylene-l9-nor-vitamin D compounds of the general structure IV may
be synthesized using the A-ring synthon 8 and the appropriate Windaus-
Grundmann ketone II
having the desired side chain structure. Thus, for example, Wittig-Horner
coupling of the
lithium phosphinoxy carbanion generated from 8 and n-butyllithium with the
protected 25-
hydroxy Grundmann's ketone 9 prepared according to published procedure
[Sicinski et al., J.
Med. Chem. 37, 3730 (1994)] gave the expected protected vitamin compound 10.
This, after
deprotection with AG 50W-X4 cation exchange resin afforded la,25-dihydroxy-2-
methylene-
19-nor-vitamin D3 (11).
The C-20 epimerization was accomplished by the analogous coupling of the
phosphine oxide 8 with protected 20(S)-25-hydroxy Grundmann's ketone 13
(SCHEME II)
and provided 19-nor-vitamin 14 which after hydrolysis of the hydroxy-
protecting groups gave
20(S)-1a,25-dihydroxy-2-methylene-19-nor-vitamin D3 (15).
-14-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
As noted above, other 2-methylene- 1 9-nor-vitamin D analogs may be
synthesized by
the method disclosed herein. For example, la-hydroxy-2-methylene-l9-nor-
vitamin D3 can
be obtained by providing the Cnluldmann's ketone (g).
This invention is described by the following illustrative examples. In these
examples
specific products identified by Arabic numerals (e.g. 1, 2, 3, etc) refer to
the specific structures
so identified in the preceding description and in the SCHEME I and SCHEME II.
EXAMPLE 1
Preparation of la,25-dihydroxy-2-methylene-19-nor-vitamin D3 (11).
Referring first to SCHEME I the starting methyl quinicate derivative 1 was
obtained
from commercial (-)-quinic acid as described previously [Perlman et al.,
Tetrahedron Lett. 32,
7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191]. 1: mp. 82-82.5 C
(from hexane),
1H NMR (CDC13) 0.098, 0.110, 0.142, and 0.159 (each 3H, each s, 4 x SiCH3),
0.896 and
0.911 (9H and 9H, each s, 2 x Si-t-Bu), 1.820 (1H, dd, J = 13.1, 10.3 Hz),
2.02 (1H, ddd, J =
14.3, 4.3, 2.4 Hz), 2.09 (1 H, dd, J = 14.3, 2.8 Hz), 2.19 (1 H, ddd, J =
13.1, 4.4, 2.4 Hz), 2.3 1
(1 H, d, J = 2.8 Hz, OH), 3.42 (1 H, m; after D20 dd, J = 8.6, 2.6 Hz), 3.77
(3 H, s), 4.12 (1 H,
m), 4.37 (1H, m), 4.53 (1H, br s, OB).
(a) Oxidation of 4-hydroxy group in methyl quinicate derivative 1.
(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-
oxocyclohexanecarboxylic Acid
Methyl Ester (2). To a stirred mixture of ruthenium(III) chloride hydrate (434
mg, 2.1 mmol)
and sodium periodate (10.8 g, 50.6 mmol) in water (42 mL) was added a solution
of methyl
quinicate 1 (6.09 g, 14 mmol) in CC14/CH3CN (1:1, 64 mL). Vigorous stirring
was continued
for 8 h. Few drops of 2-propanol were added, the mixture was poured into water
and extracted
with chloroform. The organic extracts were combined, washed with water, dried
(MgSO4) and
evaporated to give a dark oily residue (ca. 5 g) which was purified by flash
chromatography.
Elution with hexane/ethyl acetate (8:2) gave pure, oily 4-ketone 2 (3.4 g,
56%): 1H NMR
(CDC13) 8 0.054, 0.091, 0.127, and 0.132 (each 3H, each s, 4 x SiCH3), 0.908
and 0.913 (9H
and 9H, each s, 2 x Si-tBu), 2.22 (1H, dd, J = 13.2, 11.7 Hz), 2.28 (1H, - dt,
J = 14.9, 3.6 Hz),
2.37 (1H, dd, J= 14.9, 3.2 Hz), 2.55 (1H, ddd, J = 13.2, 6.4, 3.4 Hz), 3.79
(3H, s), 4.41 (1H, t,
-15-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
J- 3.5 Hz), 4.64 (1H, s, OR), 5.04 (1H, dd, J = 11.7, 6.4 Hz); MS m/z
(relative intensity) no
M+, 375 (M+ - t-Bu, 32), 357 (M+ - t-Bu - H20, 47), 243 (31), 225 (57), 73
(100).
(b) Wittig reaction of the 4-ketone 2. -
(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-
methylenecyclohexanecarboxylic
Acid Methyl Ester (3). To the methyltriphenylphoshonium bromide (2.813 g, 7.88
mmol) in
anhydrous THF (32 mL) at 0 C was added dropwise n-BuLi (2.5 M in hexanes, 6.0
mL, 15
mmol) under argon with stirring. Another portion of MePh3P+Br (2.813 g, 7.88
mmol) was
then added and the solution was stirred at 0 C for 10 min and at room
temperature for 40
min. The orange-red mixture was again cooled to 0 C and a solution of 4-ketone
2 (1.558 g,
3.6 mmol) in anhydrous THF (16 + 2 mL) was syphoned to reaction flask during
20 min. The
reaction mixture was stirred at 0 C for 1 h and and at room temperature for 3
h. The mixture
was then carefully poured into brine cont. 1% HCl and extracted with ethyl
acetate and
benzene. The combined organic extracts were washed with diluted NaHCO3 and
brine, dried
(MgSO4) and evaporated to give an orange oily residue (ca. 2.6 g) which was
purified by flash
chromatography. Elution with hexane/ethyl acetate (9:1) gave pure 4-methylene
compound 3
as a colorless oil (368 mg, 24%): 1H NMR (CDC13) b 0.078, 0.083, 0.092, and
0.115 (each
3H, each s, 4 x SiCH3), 0.889 and 0.920 (9H and 9H, each s, 2 x Si-t-Bu),
1.811 (1H, dd, J
12.6, 11.2 Hz), 2.10 (2H, m), 2.31 (1H, dd, J= 12.6, 5.1 Hz), 3.76 (3H, s),
4.69 (1H, t, J = 3.1
Hz), 4.78 (1H, m), 4.96 (2H, m; after D20 1H, br s), 5.17 (1H, t, J= 1.9 Hz);
MS m/z (relative
intensity) no M+, 373 (M+ - t-Bu, 57), 355 (M+ - t-Bu - H20, 13), 341 (19),
313 (25), 241
(33), 223 (37), 209 (56), 73 (100).
(c) Reduction of ester group in the 4-methylene compound 3.
[(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-
methylenecyclohexyl]methanol
(4). (i) To a stirred solution of the ester 3 (90 mg, 0.21 mmol) in anhydrous
THF (8 mL)
lithium aluminum hydride (60 mg, 1.6 mmol) was added at 0 C under argon. The
cooling
bath was removed after 1 h and the stirring was continued at 6 C for 12 h and
at room
temperature for 6 h. The excess of the reagent was decomposed with saturated
aq. Na2SO4,
and the mixture was extracted with ethyl acetate and ether, dried (MgSO4) and
evaporated.
Flash chromatography of the residue with hexane/ethyl acetate (9:1) afforded
unreacted
-16-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
substrate (12 mg) and a pure, crystalline diol 4(35 mg, 48% based on recovered
ester 3): 1H
NMR (CDC13 + D20) 8 0.079, 0.091, 0.100, and 0.121 (each 3H, each s, 4 x
SiCH3), 0.895
and 0.927 (9H and 9H, each s, 2 x Si-t-Bu), 1.339 (1H, t, J- 12 Hz), 1.510
(1H, dd, J = 14.3,
2.7 Hz), 2.10 (2H, m), 3.29 and 3.40 (1 H and 1H, each d, J = 11.0 Hz), 4.66
(1 H, t, J- 2.8
Hz), 4.78 (1 H, m), 4.92 (1H, t, J = 1.7 Hz), 5.13 (111, t, J = 2.0 Hz); MS
m/z (relative
intensity) no M+, 345 (M+ - t-Bu, 8), 327 (M+ - t-Bu - H20, 22), 213 (28), 195
(11), 73
(100).
(ii) Diisobutylaluminum hydride (1.5 M in toluene, 2.0 mL, 3 mmol) was added
to a solution
of the ester 3 (215 mg, 0.5 mmol) in anhydrous ether (3 mL) at -78 C under
argon. The
mixture was stirred at -78 C for 3 h and at -24 C for 1.5 h, diluted with
ether (10 mL) and
quenched by the slow addition of 2N potassium sodium tartrate. The solution
was warmed to
room temperature and stirred for 15 min, then poured into brine and extracted
with ethyl
acetate and ether. The organic extracts were combined, washed with diluted
(ca. 1%) HCI, and
brine, dried (MgSO4) and evaporated. The crystalline residue was purified by
flash
chromatography. Elution with hexane/ethyl acetate (9:1) gave crystalline dio14
(43 mg, 24%).
(d) Cleavage of the vicinal dio14.
(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-4-methylenecyclohexanone (5).
Sodium
periodate saturated water (2.2 mL) was added to a solution of the diol 4(146
mg, 0.36 mmol)
in methanol (9 mL) at 0 C. The solution was stirred at 0 C for 1 h, poured
into brine and
extracted with ether and benzene. The organic extracts were combined, washed
with brine,
dried (MgSO4) and evaporated. An oily residue was dissolved in hexane (1 mL)
and applied
on a silica Sep-Pak cartridge. Pure 4-methylenecyclohexanone derivative 5 (110
mg, 82%)
was eluted with hexane/ethyl acetate (95:5) as a colorless oil: 1H NMR (CDC13)
S 0.050 and
0.069 (6H and 6H, each s, 4 x SiCH3), 0.881 (18H, s, 2 x Si-t-Bu), 2.45 (2H,
ddd, J = 14.2,
6.9, 1.4 Hz), 2.64 (2H, ddd, J= 14.2, 4.6, 1.4 Hz), 4.69 (2H, dd, J= 6.9, 4.6
Hz), 5.16 (2H, s);
MS m/z (relative intensity) no M+, 355 (M+ - Me, 3), 313 (M+ - t-Bu, 100), 73
(76).
(e) Preparation of the allylic ester 6.
[(3'R,5'R)-3',5'-Bis[(tert-butyldimethylsilyl)oxy]-4'-
methylenecyclohexylidene]acetic Acid
Methyl Ester (6). To a solution of diisopropylamine (37 L, 0.28 mmol) in
anhydrous THF
-17-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
(200 L) was added n-BuLi (2.5 M in hexanes, 113 L, 0.28 mmol) under argon at
-78 C
with stirring, and methyl(trimethylsilyl)acetate (46 L, 0.28 mmol) was then
added. After 15
min, the keto compound 5 (49 mg, 0.132 mmol) in anhydrous THF (200 + 80 L)
was added
dropwise. The solution was stirred at -78 C for 2 h and the reaction mixture
was quenched
with saturated NH4C1, poured into brine and extracted with ether and benzene.
The combined
organic extracts were washed with brine, dried (MgSO4) and evaporated. The
residue was
dissolved in hexane (1 mL) and applied on a silica Sep-Pak cartridge. Elution
with hexane and
hexane/ethyl acetate (98:2) gave a pure allylic ester 6 (50 mg, 89%) as a
colorless oil: 1H
NMR (CDC13) S 0.039, 0.064, and 0.076 (6H, 3H, and 3H, each s, 4 x SiCH3),
0.864 and
0.884 (9H and 9H, each s, 2 x Si-t-Bu), 2.26 (1H, dd, J=12.8, 7.4 Hz), 2.47
(1H, dd, J= 12.8,
4.2Hz),2.98(1H,dd,J=13.3,4.0Hz),3.06(1H,dd,J=13.3,6.6Hz),3.69(3H,s),4.48
(2H, m), 4.99 (2H, s), 5.74 (1 H, s); MS m/z (relative intensity) 426 (M+, 2),
411 (M+ - Me,
4), 369 (M+ - t-Bu, 100), 263 (69).
(f) Reduction of the allylic ester 6.
2- [(3' R, 5' R)-3' , 5' -B is [(tert-butyldimethylsilyl) oxy] -4' -methyl
enecyclohexylidene] ethanol
(7). Diisobutylaluminum hydride (1.5 M in toluene, 1.6 mL, 2.4 mmol) was
slowly added to a
stirred solution of the allylic ester 6 (143 mg, 0.33 mmol) in
toluene/methylene chloride (2:1,
5.7 mL) at -78 C under argon. Stirring was continued at -78 C for 1 h and at
-46 C
(cyclohexanone/dry ice bath) for 25 min. The mixture was quenched by the slow
addition of
potassium sodium tartrate (2N, 3 mL), aq. HCl (2N, 3 mL) and H20 (12 mL), and
then diluted
with methylene chloride (12 mL) and extracted with ether and benzene. The
organic extracts
were combined, washed with diluted (ca. 1%) HCI, and brine, dried (MgSO4) and
evaporated.
The residue was purified by flash chromatography. Elution with hexane/ethyl
acetate (9:1)
gave crystalline allylic alcohol 7 (130 mg, 97%): 1H NMR (CDC13) 0.038, 0.050,
and 0.075
(3H, 3H, and 6H, each s, 4 x SiCH3), 0.876 and 0.904 (9H and 9H, each s, 2 x
Si-t-Bu), 2.12
(1H,dd,J=12.3, 8.8 Hz), 2.23 (1H,dd,J=13.3,2.7Hz),2.45(1H,dd,J=12.3,4.8Hz),
2.51 (1H, dd, J 13.3, 5.4 Hz), 4.04 (111, m; after D20 dd, J=12.0, 7.0 Hz),
4.17 (1 H, m;
after D20 dd, J 12.0, 7.4 Hz), 4.38 (1H, m), 4.49 (1H, m), 4.95 (1H, br s),
5.05 (1H, t, J=
1.7 Hz), 5.69 (1H, - t, J= 7.2 Hz); MS m/z (relative intensity) 398 (M+, 2),
383 (M+ - Me, 2),
365 (M+ - Me - H20, 4), 341 (M+ - t-Bu, 78), 323 (1V1+ - t-Bu - H20, 10), 73
(100).
-18-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
(g) Conversion of the allylic alcohol 7 into phosphine oxide 8.
[2- [(3' R, 5' R)-3' , 5' -B i s[(tert-butyldimethylsilyl) oxy] -4' -
methylenecyclohexylidene]ethyl]diphenylphosphine Oxide (8). To the allylic
alcohol 7 (105
mg, 0.263 mmol) in anhydrous THF (2.4 mL) was added n-BuLi (2.5 M in hexanes,
105 L,
0.263 mmol) under argon at 0 C. Freshly recrystallized tosyl chloride (50.4
mg, 0.264 mmol)
was dissolved in anhydrous THF (480 L)and added to the allylic alcohol-BuLi
solution. The
mixture was stirred at 0 C for 5 min and set aside at 0 C. In another dry
flask with air
replaced by argon, n-BuLi (2.5 M in hexanes, 210 L, 0.525 mmol) was added to
Ph2PH (93
L, 0.534 mmol) in anhydrous THF (750 L) at 0 C with stirring. The red
solution was
syphoned under argon pressure to the solution of tosylate until the orange
color persisted (ca.
1/2 of the solution was added). The resulting mixture was stirred an
additional 30 min at 0 C,
and quenched by addition of H20 (30 l). Solvents were evaporated under
reduced pressure
and the residue was redissolved in methylene chloride (2.4 mL) and stirred
with 10% H202 at
0 C for 1 h. The organic layer was separated, washed with cold aq. sodium
sulfite and H20,
dried (MgSO4) and evaporated. The residue was subjected to flash
chromatography. Elution
with benzene/ethyl acetate (6:4) gave semicrystalline phosphine oxide 8 (134
mg, 87%): 1H
NMR (CDC13) S 0.002, 0.011, and 0.019 (3H, 3H, and 6H, each s, 4 x SiCH3),
0.855 and
0.860 (9H and 9H, each s, 2 x Si-t-Bu), 2.0 - 2.1 (3H, br m), 2.34 (1H, m),
3.08 (1H, m), 3.19
(1H, m), 4.34 (2H, m), 4.90 and 4.94 (1H and 1H, each s,), 5.35 (1H, - q, J =
7.4 Hz), 7.46
(4H, m), 7.52 (2H, m), 7.72 (4H, m); MS m/z (relative intensity) no M+, 581
(M+ - 1, 1), 567
(M+ - Me, 3), 525 (M+ - t-Bu, 100), 450 (10), 393 (48).
(h) Wittig-Homer coupling of protected 25-hydroxy Grundmann's ketone 9 with
the
phosphine oxide 8.
la,25-Dihydroxy-2-methylene-19-nor-vitamin D3 (11). To a solution of phosphine
oxide 8
(33.1 mg, 56.8 mol) in anhydrous THF (450 L) at 0 C was slowly added n-BuLi
(2.5 M in
hexanes, 23 L, 57.5 mol) under argon with stirring. The solution turned deep
orange. The
mixture was cooled to -78 C and a precooled (-78 C) solution of protected
hydroxy ketone 9
(9.0 mg, 22.8 mol), prepared according to published procedure [Sicinski et
al., J. Med.
Chem. 37, 3730 (1994)], in anhydrous THF (200 + 100 L) was slowly added. The
mixture
was stirred under argon at -78 C for 1 h and at 0 C for 18 h. Ethyl acetate
was added, and
-19-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
the organic phase was washed with brine, dried (MgSO4) and evaporated. The
residue was
dissolved in hexane and applied on a silica Sep-Pak cartridge, and washed with
hexane/ethyl
acetate (99:1, 20 mL) to give 19-nor-vitamin derivative 10 (13.5 mg, 78%). The
Sep-Pak was
then washed with hexane/ethyl acetate (96:4, 10 mL) to recover some unchanged
C,D-ring
ketone 9 (2 mg), and with ethyl acetate (10 mL) to recover diphenylphosphine
oxide (20 mg).
For analytical purpose a sample of protected vitamin 10 was further purified
by HPLC (6.2
mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/ethyl acetate (99.9:0.1)
solvent
system. Pure compound 10 was eluted at Rv 26 mL as a colorless oil: UV (in
hexane) Xmax
244, 253, 263 nm; 1H NMR (CDC13) 8 0.025, 0.049, 0.066, and 0.080 (each 3H,
each s, 4 x
SiCH3), 0.546 (3H, s, 18-H3), 0.565 (6H, q, J = 7.9 Hz, 3 x SiCH2), 0.864 and
0.896 (9H and
9H, each s, 2 x Si-t-Bu), 0.931 (3H, d, J= 6.0 Hz, 21-H3), 0.947 (9H, t, J =
7.9 Hz, 3 x
SiCH2CH3), 1.188 (6H, s, 26- and 27-H3), 2.00 (2H, m), 2.18 (1H, dd, J= 12.5,
8.5 Hz, 4(3-
H), 2.33 (1H, dd, J = 13.1, 2.9 Hz, 10(3-H), 2.46 (1H, dd, J= 12.5, 4.5 Hz, 4a-
H), 2.52 (1H,
dd, J = 13.1, 5.8 Hz, 10a-H), 2.82 (1H, br d, J= 12 Hz, 9(3-H), 4.43 (2H, m,
1(3- and 3a-H),
4.92 and 4.97 (1 H and 1 H, each s, =CH2), 5.84 and 6.22 (1 H and 1 H, each d,
J = 11.0 Hz, 7-
and 6-H); MS m/z (relative intensity) 758 (M+, 17), 729 (M+ - Et, 6), 701 (M+ -
t-Bu, 4), 626
(100), 494 (23), 366 (50), 73 (92).
Protected vitamin 10 (4.3 mg) was dissolved in benzene (150 L) and the resin
(AG
50W-X4, 60 mg; prewashed with methanol) in methanol (800 L) was added. The
mixture
was stirred at room temperature under argon for 17 h, diluted with ethyl
acetate/ether (1:1, 4
mL) and decanted. The resin was washed with ether (8 mL) and the combined
organic phases
washed with brine and saturated NaHCO3' dried (MgSO4) and evaporated. The
residue was
purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/2-
propanol
(9:1) solvent system. Analytically pure 2-methylene-l9-nor-vitamin 11 (2.3 mg,
97%) was
collected at Ry 29 mL (1a,25-dihydroxyvitamin D3 was eluted at Rv 52 mL in the
same
system) as a white solid: UV (in EtOH) Xmax 243.5, 252, 262.5 nm; 1H NMR
(CDC13) 8
0.552 (3H, s, 18-H3), 0.941 (3H, d, J= 6.4 Hz, 21-H3), 1.222 (6H, s, 26- and
27-H3), 2.01
(2H, m), 2.27 - 2.36 (2H, m), 2.58 (1H, m), 2.80 - 2.88 (2H, m), 4.49 (2H, m,
1(3- and 3a-H),
5.10 and 5.11 (1H and 1H, each s, =CH2), 5.89 and 6.37 (1H and 1H, each d, J =
11.3 Hz, 7-
and 6-H); MS m/z (relative intensity) 416 (M+, 83), 398 (25), 384 (31), 380
(14), 351 (20),
313 (100).
-20-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
EXAMPLE 2
Preparation of 20(S)-1a,25-dihydroxy-2-methylene-19-nor-vitamin D3 (15).
SCHEME II illustrates the preparation of protected 20(S)-25-hydroxy
Grundmann's
ketone 13, and its coupling with phosphine oxide 8 (obtained as described in
Example 1).
(a) Silylation of hydroxy ketone 12.
20(S)-25-[(Triethylsilyl)oxy]-des-A,B-cholestan-8-one (13). A solution of the
ketone 12
(Tetrionics, Inc.; 56 mg, 0.2 mmol) and imidazole (65 mg, 0.95 mmol) in
anhydrous DMF
(1.2 mL) was treated with triethylsilyl chloride (95 L, 0.56 mmol), and the
mixture was
stirred at room temperature under argon for 4 h. Ethyl acetate was added and
water, and the
organic layer was separated. The ethyl acetate layer was washed with water and
brine, dried
(MgSO4) and evaporated. The residue was passed through a silica Sep-Pak
cartridge in
hexane/ethyl acetate (9:1), and after evaporation, purified by HPLC (9.4 mm x
25 cm Zorbax-
Sil column, 4 mL/min) using hexane/ethyl acetate (9:1) solvent system. Pure
protected
hydroxy ketone 13 (55 mg, 70%) was eluted at Ry 35 mL as a colorless oil: 1H
NMR
(CDC13) S 0.566 (6H, q, J= 7.9 Hz, 3 x SiCH2), 0.63 8 (3H, s, 18-H3), 0.859
(3H, d, J = 6.0
Hz, 21-H3), 0.947 (9H, t, J = 7.9 Hz, 3 x SiCH2CH3), 1.196 (6H, s, 26- and 27-
H3), 2.45 (1H,
dd, J = 11.4, 7.5 Hz, 14a-H).
(b) Wittig-Horner coupling of protected 20(,S)-25-hydroxy Grundmann's ketone
13
with the phosphine oxide 8.
20(S)-1a,25-Dihydroxy-2-methylene-19-nor-vitamin D3 (15). To a solution of
phosphine
oxide 8 (15.8 mg, 27.1 mol) in anhydrous THF (200 L) at 0 C was slowly added
n-BuLi
(2.5 M in hexanes, 11 L, 27.5 mol) under argon with stirring. The solution
turned deep
orange. The mixture was cooled to -78 C and a precooled (-78 C) solution of
protected
hydroxy ketone 13 (8.0 mg, 20.3 mol) in anhydrous THF (100 L) was slowly
added. The
mixture was stirred under argon at -78 C for 1 h and at 0 C for 18 h. Ethyl
acetate was
added, and the organic phase was washed with brine, dried (MgSO4) and
evaporated. The
residue was dissolved in hexane and applied on a silica Sep-Pak cartridge, and
washed with
-21-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
with hexane/ethyl acetate (99.5:0.5, 20 mL) to give 19-nor-vitamin derivative
14 (7 mg, 45%)
as a colorless oil. The Sep-Pak was then washed with hexane/ethyl acetate
(96:4, 10 mL) to
recover some unchanged C,D-ring ketone 13 (4 mg), and with ethyl acetate (10
mL) to recover
diphenylphosphine oxide (9 mg). For analytical purpose a sample of protected
vitamin 14 was
further purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min) using
hexane/ethyl
acetate (99.9:0.1) solvent system.
14: UV (in hexane) a,max 244, 253.5, 263 nm; 1H NMR (CDC13) 8 0.026, 0.049,
0.066, and
0.080 (each 3H, each s, 4 x SiCH3), 0.541 (3H, s, 18-H3), 0.564 (6H, q, J= 7.9
Hz, 3 x
SiCH2), 0.848 (3H, d, J= 6.5 Hz, 21-1-13), 0.864 and 0.896 (9H and 9H, each s,
2 x Si-t-Bu),
0.945 (9H, t, J= 7.9 Hz, 3 x SiCH2CH3), 1.188 (6H, s, 26- and 27-H3), 2.15 -
2.35 (4H, br
m), 2.43 - 2.53 (3H, br m), 2.82 (1H, br d, J = 12.9 Hz, 9(3-H), 4.42 (2H, m,
1(3- and 3a-H),
4.92 and 4.97 (1 H and 1 H, each s, =CH2), 5.84 and 6.22 (1 H and 1 H, each d,
J = 11.1 Hz, 7-
and 6-H); MS m/z (relative intensity) 758 (M+, 33), 729 (M+ - Et, 7), 701 (M+ -
t-Bu, 5), 626
(100), 494 (25), 366 (52), 75 (82), 73 (69).
Protected vitamin 14 (5.0 mg) was dissolved in benzene (160 L) and the resin
(AG
50W-X4, 70 mg; prewashed with methanol) in methanol (900 L) was added. The
mixture
was stirred at room temperature under argon for 19 h, diluted with ethyl
acetate/ether (1:1, 4
mL) and decanted. The resin was washed with ether (8 mL) and the combined
organic phases
washed with brine and saturated NaHCO3, dried (MgSO4) and evaporated. The
residue was
purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/2-
propanol
(9:1) solvent system. Analytically pure 2-methylene- 1 9-nor-vitamin 15 (2.6
mg, 95%) was
collected at RV 28 mL [(20R)-analog was eluted at Rv 29 mL and la,25-
dihydroxyvitamin
D3 at Rv 52 mL in the same system] as a white solid: UV (in EtOH) Xlnax 243.5,
252.5, 262.5
nm; 1H NMR (CDC13) S 0.551 (3H, s, 18-113), 0.858 (311, d, J= 6.6 Hz, 21-H3),
1.215 (6H, s,
26- and 27-113), 1.95 - 2.04 (2H, m), 2.27 - 2.35 (2H, m), 2.58 (1H, dd, J =
13.3, 3.7 Hz), 2.80
- 2.87 (2H, m), 4.49 (2H, m, 1(3- and 3a-H), 5.09 and 5.11 (1H and 1H, each s,
=CH2), 5.89
and 6.36 (1H and 1H, each d, J=11.3 Hz, 7- and 6-H); MS m/z (relative
intensity) 416 (M+,
100), 398 (26), 380 (13), 366 (21), 313 (31).
BIOLOGICAL ACTIVITY OF 2-METHYLENE-SUBSTITUTED
19-NOR-1,25-(OH)2D3 COMPOUNDS AND THEIR 20(S)-ISOMERS
The introduction of a methylene group to the 2-position of 19-nor-1,25-(OH)2D3
or
its 20(S)-isomer had little or no effect on binding to the porcine intestinal
vitamin D receptor.
-22-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
All compounds bound equally well to the porcine receptor including the
standard 1,25-
(OH)2D3 (Figure 1). It might be expected from these results that all of these
compounds
would have equivalent biological activity. Surprisingly, however, the 2
methylene
substitutions produced highly selective analogs with their primary action on
bone. When
given for 7 days in a chronic mode, the most potent compound tested was the 2-
methylene-19-
nor-20(S)-1,25-(OH)2D3 (Table 1). When given at 130 pmol/day, its activity on
bone
calcium mobilization (serum calcium) was of the order of at least 10 and
possible 100-1,000
times more than that of the native hormone. Under identical conditions, twice
the dose of
1,25-(OH)2D3 gave a serum calcium value of 13.8 mg/100 ml of serum calcium at
the 130
pmol dose. When given at 260 pmol/day, it produced the astounding value of 14
mg/100 ml
of seru.m calcium at the expense of bone. To show its selectivity, this
compound produced no
significant change in intestinal calcium transport at either the 130 or 260
pmol dose, while
1,25-(OH)2D3 produced the expected elevation of intestinal calcium transport
at the only dose
tested, i.e. 260 pmol/day. The 2-methylene-19-nor-1,25-(OH)2D3 also had
extremely strong
bone calcium mobilization at both dose levels but also showed no intestinal
calcium transport
activity. The bone calcium mobilization activity of this compound is likely to
be 10-100 times
that of 1,25-(OH)2D3. These results illustrate that the 2-methylene and the
20(S)-2-methylene
derivatives of 19-nor-1,25-(OH)2D3 are selective for the mobilization of
calcium from bone.
Table 2 illustrates the response of both intestine and serum calcium to a
single large dose of
the various compounds; again, supporting the conclusions derived from Table 1.
The results in Figure 2 illustrate that 2-methylene-19-nor-20(S)-1,25-(OH)2D3
is
extremely potent in inducing differentiation of HL-60 cells to the moncyte.
The 2-methylene-
19-nor compound had activity similar to 1,25-(OH)2D3. These results illustrate
the potential
of the 2-methylene-19-nor-20(S)-1,25-(OH)2D3 and 2-methylene-19-nor-1,25-
(OH)2D3
compounds as anti-cancer agents, especially against leukemia, colon cancer,
breast cancer and
prostate cancer, or as agents in the treatment of psoriasis.
Competitve binding of the analogs to the porcine intestinal receptor was
carried out
by the method described by Dame et al (Biochemistry 25, 4523-4534, 1986).
The differentiation of HL-60 promyelocytic into monocytes was determined as
described by Ostrem et al (J. Biol. Chem. 262, 14164-14171, 1987).
- 23 -
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Table 1. Response of Intestinal Calcium Transport and Serum Calcium (Bone
Calcium Mobilization) Activity to Chronic Doses of 2-Methylene Derivatives of
19-Nor-
1,25-(OH)2D3 and its 20(S) Isomers
Intestinal Calcium
Dose Transport Serum Calcium
Group (pmol/day/7 days) (S/M) (mg/100 ml)
Vitamin D Deficient Vehicle 5.5 0.2 5.1 0.16
1,25-(OH)2D3 Treated 260 6.2 0.4 7.2 0.5
2-Methylene-19-Nor-1,25- 130 5.3 0.4 9.9 0.2
(OH)2D3 260 4.9 0.6 9.6 0.3
2-Methylene-19-Nor-20(S)- 130 5.7 0.8 13.8 0.5
1,25-(OH)2D3 260 4.6 0.7 14.4 0.6
Male weanling rats were obtained from Sprague Dawley Co. (Indianapolis, IN)
and
fed a 0.47% calcium, 0.3% phosphorus vitamin D-deficient diet for 1 week and
then given the
same diet containing 0.02% calcium, 0.3% phosphorus for 2 weeks. During the
last week they
were given the indicated dose of compound by intraperitoneal injection in 0.1
ml 95%
propylene glycol and 5% ethanol each day for 7 days. The control animals
received only the
0.lml of 95% propylene glycol, 5% ethanol. Twenty-four hours after the last
dose, the rats
were sacrificed and intestinal calcium transport was determined by everted sac
technique as
previously described and serum calcium determined by atomic absorption
spectrometry on a
mode13110 Perkin Elmer instrument (Norwalk, CT). There were 5 rats per group
and the
values represent mean SEM.
-24-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Table 2. Response of Intestinal Calcium Transport and Serum Calcium (Bone
Calcium Mobilization) Activity to a Single Dose of the 2-Methylene-Derivatives
of 19-Nor-
1,25-(OH)2D3 and its 20(S) Isomers
Intestinal Calcium
Transport Serum Calcium
Group (S/M) (mg/100 ml)
-D Control 4.2 0.3 4.7 0.1
1,25-(OH)2D3 5.8 0.3 5.7 0.2
2-Methylene-19-Nor-1,25-(OH)2D3 5.3 0.5 6.4 0.1
2-Methylene-19-Nor-20(S)-1,25-(OH)2D3 5.5 0.6 8.0 0.1
Male Holtzman strain weanling rats were obtained from the Sprague Dawley Co.
(Indianapolis, IN) and fed the 0.47% calcium, 0.3% phosphorus diet described
by Suda et al.
(J. Nutr. 100, 1049-1052, 1970) for 1 week and then fed the same diet
containing 0.02%
calcium and 0.3% phosphorus for 2 additional weeks. At this point, they
received a single
intrajugular injection of the indicated dose dissolved in 0.1 ml of 95%
propylene glycol/5%
ethanol. Twenty-four hours later they were sacrificed and intestinal calcium
transport and
serum calcium were determined as described in Table 1. The dose of the
compounds was 650
pmol and there were 5 animals per group. The data are expressed as mean SEM.
EXAMPLE 3
Preparation of 20(S)-1a,25-Dihydroxy-2-methylene-26,27-dihomo-19-norvitamin
D3 (35). Reference is made to SCHEME III.
20(S)-25-[(Triethylsilyl)oxy]-des-A,B-26,27-dihomocholestan-8-one (32). To a
solution of 20(S)-25-hydroxy Grundmann's ketone analog 31 (Tetrionics,
Madison, WI;
18.5 mg, 0.06 mmol) in anhydrous CH2C12 (60 L) was added 2,6-lutidine (17.4
L, 0.15
mmol) and triethylsilyl trifluoromethanesulfonate (20.3 L, 0.09 mmol). The
mixture was
stirred at room temperature under argon for 1 h. Benzene was added and water,
and the
organic layer was separated, washed with sat. CuSO4 and water, dried (MgSO4)
and
evaporated. The oily residue was redissolved in hexane and applied on a silica
Sep-Pak
cartridge (2 g). Elution with hexane (10 mL) gave a small quantity of less
polar
-25-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
compounds; further elution with hexane/ethyl acetate (9:1) provided the
silylated ketone.
Final purification was achieved by HPLC (10-mm x 25-cm Zorbax-Sil column, 4
mL/min)
using hexane/ethyl acetate (95:5) solvent system. Pure protected hydroxy
ketone 32 (16.7
mg, 66%) was eluted at Rv 37 mL as a colorless oil: 'H NMR (CDC13) 0.573 (6H,
q, J =
7.9 Hz, 3 x SiCH2), 0.639 (3H, s, 18-H3), 0.825 (6H, t, J= 7.5 Hz, 26- and 27-
CH3), 0.861
(3H, d, J = 6.1 Hz, 21-H3), 0.949 (9H, t, J= 7.9 Hz, 3 x SiCH2CH3), 2.45 (1H,
dd, J
11.4, 7.6 Hz, 14a-H).
20(S')-1a,25-Dihydroxy-2-methylene-26,27-dihomo-l9-norvitamin D3 (35). To a
solution of phosphine oxide 33 (9.1 mg, 15.6 mol) in anhydrous THF (150 L)
at 0 C
was slowly added n-BuLi (2.5 M in hexanes, 7 L, 17.5 mol) under argon with
stirring.
The solution turned deep orange. It was stirred for 10 min at 0 C, then cooled
to -78 C
and a precooled (-78 C) solution of protected hydroxy ketone 32 (16.5 mg,
39.0 mol) in
anhydrous THF (300 + 100 L) was slowly added. The mixture was stirred under
argon at
-78 C for 1.5 h and at 0 C for 19 h. Water and ethyl acetate were added, and
the organic
phase was washed with brine, dried (MgSO4) and evaporated. The residue was
dissolved
in hexane and applied on a silica Sep-Pak cartridge, and washed with
hexane/ethyl acetate
(99.7:0.3, 20 mL) to give slightly impure 19-norvitamin derivative 34 (ca. 4
mg). The Sep-
Pak was then washed with hexane/ethyl acetate (96:4, 10 mL) to recover some
unchanged
C,D-ring ketone (contaminated with 14(3-isomer), and with ethyl acetate (10
mL) to
recover diphenylphosphine oxide 33 (ca. 6 mg) that was subsequently purified
by HPLC
(10-mm x 25-cm Zorbax-Sil column, 4 mL/min) using hexane/2-propanol (9:1)
solvent
system; pure compound 33 (5.1 mg) was eluted at Rv 36 mL. The protected
vitamin 34
was further purified by HPLC (6.2-mm x 25-cm Zorbax-Sil column, 4 mL/min)
using
hexane/ethyl acetate (99.9:0.1) solvent system. Pure compound 34 (3.6 mg, 67%
yield
considering the recovery of unreacted 33) was eluted at Rv 19 mL as a
colorless oil: UV
(in hexane) max 244.0, 252.5, 262.5 nm;1H NMR (CDC13) 0.026, 0.048, 0.066, and
0.079 (each 3H, each s, 4 x SiCH3), 0.544 (3H, s, 18-H3), 0.570 (6H, q, J =
7.9 Hz, 3 x
SiCH2), 0.821 (6H, t, J = 7.5 Hz, 26- and 27-CH3), 0.849 (3H, d, J= 6.7 Hz, 21-
H3), 0.864
and 0.896 (9H and 9H, each s, 2 x Si-t-Bu), 0.946 (9H, t, J = 7.9 Hz, 3 x
SiCH2CH3), 1.99
(2H, m), 2.18 (1H, dd, J= 12.6, 8.2 Hz, 4(3-H), 2.34 (1H, dd, J=13.0, 2.9 Hz,
10(3-H),
2.46 (1H, dd, J = 12.6, 4.3 Hz, 4 -H), 2.51 (1H, dd, J = 13.0, 6.2 Hz, 10 -H),
2.82 (1H, br
d, J=12 Hz, 9(3-H), 4.43 (2H, m, 1(3- and 3 -H), 4.92 and 4.97 (1 H and 1 H,
each s, =CH2),
-26-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
5.84 and 6.22 (1H and 1H, each d, J = 11.2 Hz, 7- and 6-H); MS m/z (relative
intensity)
786 (M+, 15), 757 (M+ - Et, 22), 729 (M+ - t-Bu, 5), 654 (100), 522 (15), 366
(43), 201
(31).
Protected vitamin 34 (3.5 mg) was dissolved in benzene (150 L) and the resin
(AG
50W-X4, 40 mg; prewashed with methanol) in methanol (550 L) was added. The
mixture
was stirred at room temperature under argon for 14 h, diluted with ethyl
acetate/ether (1:1, 4
mL) and decanted. The resin was washed with ether (8 mL) and the combined
organic phases
washed with brine and saturated NaHCO3, dried (MgS04) and evaporated. The
residue was
purified by HPLC (6.2-mm x 25-cm Zorbax-Sil column, 4 mL/min) using hexane/2-
propanol
(9:1) solvent system. Analytically pure 2-methylene- 1 9-norvitamin 35 (1.22
mg, 62%) was
collected at Rv 21 mL as a white solid: UV (in EtOH) kmax 243.5, 252.0, 262.0
nm; 1H NMR
(CDC13) 6 0.550 (3H, s, 18-H3), 0.855 (3H, d, J= 6.8 Hz, 21-H3), 0.860 (6H, t,
J= 7.5 Hz, 26-
and 27-CH3), 2.00 (3H, m), 2.30 (1H, dd, J = 13.3, 8.6 Hz, l0a-H), 2.33 (1H,
dd, J = 13.3, 6.3
Hz, 4(3-H), 2.58 (1H, dd, J = 13.3, 3.9 Hz, 4a-H), 2.82 (1H, br d, J= 12 Hz,
9(3-H), 2.85 (1H,
dd, J = 13.3, 4.7 Hz, 10(3-H), 4.48 (2H, m, 1P- and 3(x-H), 5.09 and 5.11 (1H
and 1H, each s,
=CHa), 5.89 and 6.36 (1H and 1H, each d, J=11.3 Hz, 7- and 6-H); MS m/z
(relative
intensity) 444 (M+, 100), 426 (35), 408 (11), 397 (19), 379 (32), 341 (31),
287 (32), 273 (43),
269 (28), 251 (22); exact mass calcd for C29H48O3 444.3603, found 444.3602.
BIOLOGICAL ACTIVITY OF 20(S)-la,25-DIHYDROXY-2-METHYLENE-26,27-
DIHOMO-19 NORVITAMIN D3 (35).
Competitive binding of the analogs to the porcine intestinal receptor was
carried out
by the method described by Dame et al (Biochemistry 25, 4523-4534, 1986).
The differentiation of HL-60 promyleocytic into monocytes was determined as
described by Ostrem et al (J. Biol. Chem. 262, 14164-14171, 1987).
-27-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Table 3 VDR Binding Propertiesa and HL-60 Differentiating Activitiesb of 2-
Substituted Analogs of 20(,S)-1a,25-Dihydroxy-26,27-dihomo-19-norvitamin D3
Compound Compd. VDR Binding HL-60 Differentiation
no. ED50 Binding ED50 Activity
(M) ratio (M) ratio
la,25-(OH)2D3 8.7 x 10-10 1 4.0 x 10-9 1
2-methylene-26,27-dihomo-
19-nor-20(,S')-la,25-(OH)2D3 35 4.3 x 10-9 4.9 2.6 x 10-11 0.01
aCompetitive binding of 1a,25-(OH)2D3 and the synthesized vitamin D analogs
to the porcine intestinal vitamin D receptor. The experiments were carried out
in triplicate
on two different occasions. The ED50 values are derived from dose-response
curves and
represent the analog concentration required for 50% displacement of the
radiolabeled
1 a,25-(OH)2D3 from the receptor protein. Binding ratio is the ratio of the
analog average
ED50 to the ED50 for la,25-(OH)2D3.
bInduction of differentiation of HL-60 promyelocytes to monocytes by 1a,25-
(OH)2D3 and the synthesized vitamin D analogs. Differentiation state was
determined by
measuring the percentage of cells reducing nitro blue tetrazolium (NBT). The
experiment
was repeated three times. The values ED50 are derived from dose-response
curves and
represent the analog concentration capable of inducing 50% maturation.
Differentiation
activity radio is the ratio of the analog average ED50 to the ED50 for 1a,25-
(OH)2D3.
Table 4. Support of Intestinal Calcium Transport and Bone Calcium
Mobilization by 2-Substituted Analogs of of 20(S)-1a,25-Dihydroxy u,,25-
Dihydroxy-26,27-diho
D3 in Vitamin D-Deficient Rats on a Low-Calcium Diet
Compound Compd. Amount Ca Transport S/M Serum Ca
no. (pmol) (mean SEM) (mean SEM)
none (control) 0 2.7 +0.3 4.7 ~ 0.2
la,25-(OH)2D3 260 7.2 0.6c 5.6 ~ 0.2c
2-methylene-26,27-dihomo- 35 15 4.0 0.4 dl 5.3 ~ 0.1 dl
19-nor-20(S)-la,25-(OH)2D3 32 8.2 0.6d2 7.3 ~ 0.4d2
-28-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
aWeanling male rats were maintained on a 0.47% Ca diet for 1 week and then
switched to a low-calcium diet containing 0.02% Ca for an additional 3 weeks.
During the
last week, they were dosed daily with the appropriate vitamin D compound for 7
consecutive days. All doses were administered intraperitoneally in 0.1 ml
propylene
glycol/ethanol (95:5). Controls received the vehicle. Determinations were made
24 h after
the last dose. There were at least 6 rats per group. Statistical analysis was
done by
Student's t-test. Statistical data: serosal/mucosal (S/M), b from c and d2, p
< 0.001, b from
dl , NS; serum calcium, b from c, p < 0.05, b from dl , NS, b from d2, p=
0.005.
EXAMPLE4
Preparation of 20(S)-26,27-dimethylene-1 a-hydroxy-2-methylene-24-dehydro-
19-norvitamin D3 (45); 20(S)-26,27-dimethylene-la-hydroxy-25-methoxy-2-
methylene-
19-norvitamin D3 (46); and 20(S)-1a,25-dihydroxy-26,27-dimethylene-2-methylene-
19-
norvitamin D3 (47).
Reference is made to SCHEME IV.
20(S)-25-[(Triethylsilyl)oxy]-des-A,B-26,27-dimethylene-cholestan-8-one (42).
To a solution of 20(S)-25-hydroxy Grundmann's ketone analog 41 (Tetrionics,
Madison,
WI; 15.0 mg, 0.049 mmol) in anhydrous CH2C12 (50 L) was added 2,6-lutidine
(15 L,
0.129 mmol) and triethylsilyl trifluoromethanesulfonate (17.0 L, 0.075 mmol).
The
mixture was stirred at room temperature under argon for 1 h. Benzene was added
and
water, and the organic layer was separated, washed with sat. CuSO4 and water,
dried
(MgSO4) and evaporated. The oily residue was redissolved in hexane and applied
on a
silica Sep-Pak cartridge (2 g). Elution with hexane (10 mL) gave a small
quantity of less
polar compounds; further elution with hexane/ethyl acetate (9:1) provided the
silylated
ketone. Final purification was achieved by HPLC (10-mm x 25-cm Zorbax-Sil
column, 4
mL/min) using hexane/ethyl acetate (95:5) solvent system. Pure protected
hydroxy ketone
42 (9.4 mg, 46%) was eluted at Rv 39 mL as a colorless oil: 'H NMR (CDC13)
0.576 (6H,
q, J = 7.9 Hz, 3 x SiCH2), 0.638 (3H, s, 18-H3), 0.865 (3H, d, J= 6.1 Hz, 21-
H3), 0.949
(9H, t, J= 7.9 Hz, 3 x SiCH2CH3), 2.45 (1H, dd, J = 11.4, 7.5 Hz, 14a-H).
20(S')-1 a,25-Dihydroxy-26,27-dimethylene-2-methylene-l9-norvitamin D3 (47).
To a solution of phosphine oxide 43 (17.7 mg, 30.4 mol) in anhydrous THF (300
L) at
0 C was slowly added n-BuLi (2.5 M in hexanes, 13 L, 32.5 mol) under argon
with
-29-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
stirring. The solution turned deep orange. It was stirred for 10 min at 0 C,
then cooled to -
78 C and a precooled (-78 C) solution of protected hydroxy ketone 41 (17.8
mg, 42.3
mol) in anhydrous THF (300 + 100 L) was slowly added. The mixture was stirred
under
argon at -78 C for 1.5 h and at 0 C for 18 h. Water and ethyl acetate were
added, and the
organic phase was washed with brine, dried (MgSO4) and evaporated. The residue
was
dissolved in hexane and applied on a silica Sep-Pak cartridge, and washed with
hexane/ethyl acetate (99.7:0.3, 20 mL) to give slightly impure 19-norvitamin
derivative 44
(ca. 11 mg). The Sep-Pak was then washed with hexane/ethyl acetate (96:4, 10
mL) to
recover some unchanged C,D-ring ketone (contaminated with 14(3-isomer), and
with ethyl
acetate (10 mL) to recover diphenylphosphine oxide 43 (ca. 8 mg) that was
subsequently
purified by HPLC (10-mm x 25-cm Zorbax-Sil column, 4 mL/min) using hexane/2-
propanol (9:1) solvent system; pure compound 43 (7.6 mg) was eluted at Rv 36
mL. The
protected vitamin 44 was further purified by HPLC (6.2-mm x 25-cm Zorbax-Sil
column,
4 mL/min) using hexane/ethyl acetate (99.9:0.1) solvent system. Pure compound
44 (10.1
mg, 74% yield considering the recovery of unreacted 43) was eluted at Rv 27 mL
as a
colorless oil: UV (in hexane) max 244.0, 252.5, 262.5 nm;'H NMR (CDCl3) S
0.027,
0.048, 0.067, and 0.080 (each 3H, each s, 4 x SiCH3), 0.544 (3H, s, 18-H3),
0.575 (6H, q, J
= 7.9 Hz, 3 x SiCH2), 0.854 (3H, d, J= 6.1 Hz, 21-H3), 0.866 and 0.896 (9H and
9H, each
s, 2 x Si-t-Bu), 0.947 (9H, t, J= 7.9 Hz, 3 x SiCH2CH3), 1.99 (211, m), 2.18
(1H, dd, J =
12.8, 8.6 Hz, 4(3-H), 2.34 (1H, dd, J = 13.2, 2.7 Hz, 10(3-H), 2.46 (1H, dd, J
= 12.8, 4.4 Hz,
4a-H), 2.51 (1H, dd, J= 13.2, 6.0 Hz, l0a-H), 2.82 (1H, br d, J = 12 Hz, 9(3-
H), 4.42 (2H,
m, 1(3- and 3a-H), 4.92 and 4.97 (1H and 1H, each s, =CH2), 5.84 and 6.22 (1H
and 1H,
each d, J = 11.2 Hz, 7- and 6-H); MS m/z (relative intensity) 784 (M+, 8), 755
(M+ - Et, 4),
727 (M+ - t-Bu, 6), 652 (100), 520 (31), 366 (49), 199 (23).
Protected vitamin 44 (7.0 mg) was dissolved in benzene (220 L) and the resin
(AG 50W-X4, 95 mg; prewashed with methanol) in methanol (1.2 mL) was added.
The
mixture was stirred at room temperature under argon for 21 h, diluted with
ethyl
acetate/ether (1:1, 4 mL) and decanted. The resin was washed with ether (10
mL) and the
combined organic phases washed with brine and saturated NaHCO3, dried (MgSO4)
and
evaporated. The residue was separated by HPLC (6.2-mm x 25-cm Zorbax-Sil
column, 4
mL/min) using hexane/2-propanol (9:1) solvent system and the following
analytically pure
2-methylene-l9-norvitamins were isolated: 1a-hydroxy-25-dehydrovitamin 45
(0.68 mg,
17%) was collected at Rv 13 mL, la-hydroxy-25-methoxyvitamin 46 (0.76 mg, 19%)
was
-30- '
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
collected at Rv 16 mL and 1 a,25-dihydroxyvitamin 47 (2.0 mg, 51 %) was
collected at Rv
21 mL.
45: UV (in EtOH) a,max 243.5, 251.5, 262.0 nm; 1H NMR (CDC13) S 0.542 (3H, s,
18-H3),
0.847 (31-1, d, J= 6.5 Hz, 21-H3), 1.93-2.07 (411, m), 2.18-2.25 (2H, m), 2.26-
2.36 (4H, m),
2.58 (1H, dd, J=13.3, 3.9 Hz, 4a-H), 2.82 (1H, br d, J= 13 Hz, 9(3-H), 2.85
(1H, dd, J
13.3, 4.5 Hz, 10(3-H), 4.48 (2H, m, 1P- and 3a-H), 5.09 and 5.11 (11-1 and 1H,
each s,
=CH2), 5.32 (1H, m, w/2 = 7 Hz, 24-H), 5.88 and 6.36 (11-1 and 1H, each d, J=
11.1 Hz, 7-
and 6-H); MS m/z (relative intensity) 424 (M+, 100), 406 (7), 339 (16), 287
(16), 271 (24),
269 (17), 251 (12); exact mass calcd for C29H4402 424.3341, found 424.3343.
46: UV (in EtOH) %max 243.5, 252.0, 262.0 nm; 1H NMR (CDCl3) S 0.553 (3H, s,
18-113),
0.858 (31-1, d, J = 6.5 Hz, 21-H3), 1.95-2.05 (211, m), 2.30 (1H, dd, J=13.3,
8.3 Hz, l0a-
H), 2.33 (1H, dd, J=13.4, 6.0 Hz, 4(3-H), 2.58 (1H, dd, J= 13.4, 3.8 Hz, 4a-
H), 2.82 (1H,
br d, J = 13 Hz, 9P-H), 2.85 (1H, dd, J = 13.3, 4.4 Hz, 10(3-H), 3.13 (31-1,
s, OCH3), 4.48
(2H, m, 1(3- and 3a-H), 5.09 and 5.11 (11-1 and 1H, each s, =CH2), 5.89 and
6.36 (1H and
IH, each d, J= 11.2 Hz, 7- and 6-H); MS m/z (relative intensity) 456 (M-`-,
54), 424 (27),
406 (12), 339 (16), 287 (13), 271 (41), 99 (100); exact mass calcd for
C30H¾$03 456.3603,
found 456.3603.
47: UV (in EtOH) max 243.5, 252.0, 262.0 nm;'H NMR (CDCl3) S 0.551 (31-1, s,
18-H3),
0.859 (311, d, J = 6.6 Hz, 21-H3), 1.95-2.05 (2H, m), 2.30 (1H, dd, J=13.5,
8.4 Hz, 10a-
H), 2.33 (1H, dd, J= 13.3, 6.3 Hz, 4(3-H), 2.58 (1H, dd, J = 13.3, 4.0 Hz, 4a-
H), 2.82 (1H,
br d, J = 12 Hz, 9(3-H), 2.85 (1H, dd, J = 13.5, 4.4 Hz, 1, 0(3-H), 4.48 (2H,
m, 1(3- and 3a-
H), 5.09 and 5.11 (111 and 1H, each s, =CHZ), 5.89 and 6.36 (111 and 1H, each
d, J= 11.3
Hz, 7- and 6-H); MS m/z (relative intensity) 442 (M+, 100), 424 (47), 406
(15), 339 (34),
287 (27), 271 (42), 269 (36), 251 (26); exact mass calcd for C29H4603
442.3447, found
442.3442.
BIOLOGICAL ACTIVITY OF 20(S)-26,27-DIMETHYLENE-la-HYDROXY-2-
METHYLENE-24-DEHYDRO-19-NORVITAMIN D3 (45); 20(S)-26,27-
DIMETHYLENE-1 a-HYDROXY-25-METHOXY-2-METHYLENE-19-NORVITAMIN
D3 (46); AND 20(S)-1a,25-DIHYDROXY-26,27-DIMETHYLENE-2-METHYLENE-19-
NORVITAMIN D3 (47).
Competitive binding of the analogs to the porcine intestinal receptor was
carried
out by the method described by Dame et al (Biochemistry 25, 4523-4534, 1986).
-31-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
The differentiation of HL-60 promyelocytic into monocytes was determined as
described by Ostrem et al (J. Biol. Chem. 262, 14164-14171, 1987).
Table 5. VDR Binding Propertiesa and HL-60 Differentiating Activitiesb of Side
Chain Analogs of 20(S)-26,27-dimethylene-la-hydroxy-2-methylene-19-norvitamin
D3
Compound Compd. VDR Binding HL-60 Differentiation
no. ED50 Binding ED50 Activity
(M) ratio (M) ratio
1 a,25-(OH)2D3 8.7 x 10` 10 1 4.0 x 10 9 1
26,27-dimethylene-2-inethylene-
24-dehydro-19-nor-20(S)-la-OH-D3 45 2.9 x 10-8 33 4.1 x 10-9 1.0
26,27-dimethylene-2-methylene-
25-methoxy-19-nor-20(S)-la-OH-D3 46 1.5 x 10-8 17 4.3 x 10-9 1.1
26,27-dimethylene-2-methylene-
19-nor-20(S)-1a,25-(OH)2D3 47 2.7 x 10 9 3.1 3.6 x 10-11 0.01
aCompetitive binding of 1 a,25-(OH)2D3 and the synthesized vitamin D analogs
to the porcine intestinal vitamin D receptor. The experiments were carried out
in triplicate
on two different occasions. The ED50 values are derived from dose-response
curves and
represent the analog concentration required for 50% displacement of the
radiolabeled
1 a,25-(OH)2D3 from the receptor protein. Binding ratio is the ratio of the
analog average
ED50 to the ED50 for 1a,25-(OH)2D3.
bInduction of differentiation of HL-60 promyelocytes to monocytes by la,25-
(OH)2D3 and the synthesized vitamin D analogs. Differentiation state was
determined by
measuring the percentage of cells reducing nitro blue tetrazolium (NBT). The
experiment
was repeated three times. The values ED50 are derived from dose-response
curves and
represent the analog concentration capable of inducing 50% maturation.
Differentiation
activity radio is the ratio of the analog average ED50 to the ED50 for 1 a,25-
(OH)2D3.
-32-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Table 6. Support of Intestinal Calcium Transport and Bone Calcium Mobilization
by Side Chain Analogs at 20(S)-26,27-dimethylene- 1 a-hydroxy-2-methylene- 19-
norvitamin D3 in Vitamin D-Deficient Rats on a Low-Calcium Dieta
Compound Compd. Amount Ca Transport S/M Serum Ca
no. (pmol) (mean SEM) (mean SEM)
none (control) 0 2.7 ~ 0.3b 4.7 0.2b
la,25-(OH)2D3 260 7.2 ~ 0.6' 5.6 0.2'
26,27-dimethylene-2-methylene- 47 15 5.6 ~ 0.6 dl 5.4 0.2 dl
19-nor-20(S)-la,25-(OH)2D3 32 5.3 ~ 0.5d2 6.4 ~ 0.2d2
none (control) 0 3.6 ~ 0.4b 5.0 ~ 0.1b
1a,25-(OH)2D3 260 5.0 f 0.4c 6.3 ~ 0.2c
26,27-dimethylene-2-methylene- 45 65 5.5 J: 0.8 dl 5.7 ~ 0.1 dl
24-dehydro-19-nor-20(S)-la-OH-D3 260 4.3 0.5 d2 10.8 ~ 0.3 d2
26,27-dimethylene-2-methylene- 46 65 5.5 + 0.8e1 5.7 ~ 0.1el
25-methoxy-19-nor-20(S)-la-OH-D3 260 4.3 J: 0.5e2 10.8 ~ 0.3 e2
aWeanling male rats were maintained on a 0.47% Ca diet for 1 week and then
switched to a low-calcium diet containing 0.02% Ca for an additional 3 weeks.
During the
last week, they were dosed daily with the appropriate vitamin D compound for 7
consecutive days. All doses were administered intraperitoneally in 0.1 ml
propylene
glycol/ethanol (95:5). Controls received the vehicle. Determinations were made
24 h after
the last dose. There were at least 6 rats per group. Statistical analysis was
done by
Student's t-test. Statistical data: serosal/mucosal (S/M), panel 1, b from c,
p < 0.001, b
from dl and d2, p = 0.001; panel 2, b from c and el, p< 0.05, b from dZ, d~
and e2, NS;
serum calcium, panel 1, b from c, p < 0.05, b from dl, NS, b from d2, p =
0.005; panel 2, b
fromc,p<0.01,bfromd1,NS,bfromd2ande1,p=0.05,bfrome2,p<0.001.
For treatment purposes, the novel compounds of this invention defined by
formula I
may be formulated for pharmaceutical applications as a solution in innocuous
solvents, or as
an emulsion, suspension or dispersion in suitable solvents or carriers, or as
pills, tablets or
capsules, together with solid carriers, according to conventional methods
known in the art.
- 33 -
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
Any such formulations may also contain other pharmaceutically-acceptable and
non-toxic
excipients such as stabilizers, anti-oxidants, binders, coloring agents or
emulsifying or taste-
modifying agents.
The compounds may be administered orally, topically, parenterally or
transdermally.
The compounds are advantageously administered by injection or by intravenous
infusion or
suitable sterile solutions, or in the form of liquid or solid doses via the
alimentary canal, or in
the form of creams, ointments, patches, or similar vehicles suitable for
transdermal
applications. Doses of from 0.1 g to 50 g per day of the compounds are
appropriate for
treatment purposes, such doses being adjusted according to the disease to be
treated, its
severity and the response of the subject as is well understood in the art.
Since the new
compounds exhibit specificity of action, each may be suitably administered
alone, or together
with graded doses of another active vitamin D compound -- e.g. la-
hydroxyvitamin D2 or D3,
or 1a,25-dihydroxyvitamin D3 -- in situations where different degrees of bone
mineral
mobilization and calcium transport stimulation is found to be advantageous.
Compositions for use in the above-mentioned treatment of psoriasis and other
malignancies comprise an effective amount of one or more 2-alkylidene- 1 9-nor-
vitamin D
compound as defined by the above formula I as the active ingredient, and a
suitable carrier.
An effective amount of such compounds for use in accordance with this
invention is from
about 0.01 g to about 100 g per gm of composition, and may be administered
topically,
transdermally, orally or parenterally in dosages of from about 0.1 g/day to
about 100 g/day.
The compounds may be formulated as creams, lotions, ointments, topical
patches,
pills, capsules or tablets, or in liquid form as solutions, emulsions,
dispersions, or suspensions
in pharnlaceutically innocuous and acceptable solvent or oils, and such
preparations may
contain in addition other pharmaceutically innocuous or beneficial components,
such as
stabilizers, antioxidants, emulsifiers, coloring agents, binders or taste-
modifying agents.
The compounds are advantageously administered in amounts sufficient to effect
the
differentiation of promyelocytes to normal macrophages. Dosages as described
above are
suitable, it being understood that the amounts given are to be adjusted in
accordance with the
severity of the disease, and the condition and response of the subject as is
well understood in
the art.
The formulations of the present invention comprise an active ingredient in
association with a pharmaceutically acceptable carrier therefore and
optionally other
-34-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
therapeutic ingredients. The carrier must be "acceptable" in the sense of
being compatible
with the other ingredients of the formulations and not deleterious to the
recipient thereof.
Formulations of the present invention suitable for oral administration may be
in the
form of discrete units as capsules, sachets, tablets or lozenges, each
containing a
predetermined amount of the active ingredient; in the form of a powder or
granules; in the
form of a solution or a suspension in an aqueous liquid or non-aqueous liquid;
or in the form
of an oil-in-water emulsion or a water-in-oil emulsion.
Formulations for rectal administration may be in the form of a suppository
incorporating the active ingredient and carrier such as cocoa butter, or in
the form of an
enema.
Formulations suitable for parenteral administration conveniently comprise a
sterile
oily or aqueous preparation of the active ingredient which is preferably
isotonic with the blood
of the recipient.
Formulations suitable for topical administration include liquid or semi-liquid
preparations such as liniments, lotions, applicants, oil-in-water or water-in-
oil emulsions such
as creams, ointments or pastes; or solutions or suspensions such as drops; or
as sprays.
For asthma treatment, inhalation of powder, self-propelling or spray
formulations,
dispensed with a spray can, a nebulizer or an atomizer can be used. The
formulations, when
dispensed, preferably have a particle size in the range of 10 to 100 .
The formulations may conveniently be presented in dosage unit form and may be
prepared by any of the methods well known in the art of pharmacy. By the term
"dosage unit"
is meant a unitary, i.e. a single dose which is capable of being administered
to a patient as a
physically and chemically stable unit dose comprising either the active
ingredient as such or a
mixture of it with solid or liquid pharmaceutical diluents or carriers.
In its broadest application, the present invention relates to any 19-nor-2-
alkylidene
analogs of vitamin D which have the vitamin D nucleus. By vitamin D nucleus,
it is meant a
central part consisting of a substituted chain of five carbon atoms which
correspond to
positions 8, 14, 13, 17 and 20 of vitamin D, and at the ends of which are
connected at position
20 a structural moiety representing any of the typical side chains known for
vitamin D type
compounds (such as R as previously defined herein), and at position 8 the 5,7-
diene moiety
connected to the A-ring of an active 1 a-hydroxy vitamin D analog (as
illustrated by formula I
herein). Thus, various known modifications to the six-membered C-ring and the
five-
-35-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
membered D-ring typically present in vitamin D, such as the lack of one or the
other or both,
are also embraced by the present invention.
Accordingly, compounds of the following formulae Ia, are along with those of
formula I, also encompassed by the present invention:
X8
Xsi" z
,4 .r
X5"". X6
x, R7
I x X3
2
la
Y20~ A OY,
R6 R8
In the above formula Ia, the definitions of Y1, Y2, R6, R8 and Z are as
previously set forth
herein. With respect to X1, X2, X3, X4, X5, X6, X7, X8 and X9, these
substituents may be
the same or different and are selected from hydrogen or lower alkyl, i.e. a C1-
5 alkyl such as
methyl, ethyl or n-propyl. In addition, paired substituents Xl and X4 or X5,
X2 or X3 and X6
or X7, X4 or X5 and X8 or X9, when taken together with the three adjacent
carbon atoms of
the central part of the compound, which correspond to positions 8, 14, 13 or
14, 13, 17 or 13,
17, 20 respectively, can be the same or different and form a saturated or
unsaturated,
substituted or unsubstituted, carbocyclic 3, 4, 5, 6 or 7 membered ring.
Preferred compounds of the present invention may be represented by one of the
following formulae:
-36-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
R X R
y~
"4 X51~~= X6
Q ~ Y- =.
`7 "6 x, Q
X
X2 3 X3
I I
Y~O OY1 Y20 / OY1
R6 R$ R6 R8
lb Ic
x$
Q Z x4 R
x6
X4 xs Q
x, X7 Q
X3
~ X2 ~ x3
I I
`~. ,~'.
Y20`` OY1 Y20pY~
R6 R8 ZI R$
Id le
-37-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
X$ X$
Z
z
Q )(4 Q X4 Xs X4 R
Q X Xs XS~~=,, ~
7 Q Xs
X3 X1 X 7
X
'
I Z X3 I X2 X3
l I I
Y20OY, Y2O"OY,
Y2OOY1
Rs R8 Rs R8 R~ R$
If l9 Ih
In the above formulae Ib, Ic, Id, le, If, Ig and Ih, the definitions of Yl,
Y2, R6, R8, R, Z, Xl,
X2, X3, X4, X5, X6, X7 and X8 are as previously set forth herein. The
substituent Q
represents a saturated or unsaturated, substituted or unsubstituted,
hydrocarbon chain
comprised of 0, 1, 2, 3 or 4 carbon atoms, but is preferably the group -(CH2)k-
where k is an
integer equal to 2 or 3.
Methods for making compounds of formulae Ia-Ih are known. Specifically,
reference is made to International Application Number PCT/EP94/02294 filed 7
July 1994
and published 19 January 1995 under International Publication Number
W095/01960.
-38-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
SCHEME I
HOOC.,' OH MeOOC.-',_ OH MeOOC/o OH
2 steps RnC13
NaIO4
HOOH tBuMeZSiOOSRBuMe2 tBuMe2SiOOSitBuMe2
OH OH 0
(-) -Quinic acid 1 I
2
n-BuLi
O HOH2C/, OH Me00Cs,, OH
NaI04 T=, ~g4
< [--
tBuMeZSiOOSitBUMeZ tBuMe2Si0OSitBuMeZ tBuMe2Si0"" OSitBuMe2
4 3
Me3SiCnzCOCMe~
LDA
COOMe CHZOH I, n_BuLi, TsCI CH2POPtt2
I I 2. n-BuLi, Ph2PH DTBALH
---> .
3. H2O2
tBuMe2Si0OSitBuMe2 tBuMe2Si0OSitBuMe2 tBuMe2SiOv. OSitBuMe2
6 7 8
'~~..
oSiE~
n-BuLi
o 9
i~,,~, it,~~~
OH OSiEt3
1 AG 50'ri-X4 I
4
~ ~
HOOH tBuMe2SiOOSitBuMeZ
31 10
-39-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
SCHEME II
OH OSiEt3
SiEt3C1
H O N
0
12 13
CH2POPhz
.n-BuLi
tBuMe2Si0 OSitE3uMeZ
8
OH OSiEt3
AG 5
0W-X4 NOtBuMeZSiOOSftBuMe2
r
15 14
-40-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
SCHEME III
OH OSiEt3
CF3SO3SIEt3
2,6-lutidine, CH 2CI2
O O
2
CH2POPh2
nBuLi, THF
t-BuMe2SiO OSitBuMe2
3
OH OSiEt3
AG 50W X4 I
MeOH
HO~" OH t-BuMe2SiO'~OSitBuMe2
4
-41-
CA 02404548 2002-09-27
WO 01/74766 PCT/US01/10317
SCHEME IV
OH OS iEt3
CF3S03S iEt3
2,6-lutidine, CH 2CI2
O H O H
2
CH2POPh2
nBuLi, THF
t-BuMe2SiOx" OSitBuMe2
3
v OS iEt3
\
I AG 50W X4 I
I MeOH I
HO~~pH t-BuMe2SiO`~~ ~OSitBuMe~
4
OCH3 OH
V V
H& OH H& OH
6 7
-42-
